[CBMG] Cellular Biomedicine Group, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 13.5 Change: 0.2 (1.5%)
Ext. hours: Change: 0 (0%)

chart CBMG

Refresh chart

Description: Cellular Biomedicine Group, Inc., a biomedicine company, develops treatments for cancerous and degenerative diseases in Greater China. The company operates through two segments, Biomedicine and Consulting. It focuses on developing and marketing cell-based therapies to treat serious chronic and degenerative diseases, such as cancer, osteoarthritis, tissue damage, spinal muscular atrophy, various inflammatory diseases, and joint degeneration and metabolic diseases. The company develops treatments utilizing proprietary cell technologies comprising tumor cell specific dendritic cells for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint disease; human umbilical cord-derived mesenchymal progenitor cells; human embryo-derived motor neuron progenitor precursor cells; and human embryo-derived neuronal progenitor precursor cells for the treatment of central nervous system diseases. It also provides consulting services to companies who seek access to the

Fundamental Ratios
Shares Outstanding EPS-1.92 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-3.7
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-33.34% ROE-36.67% ROI
Current Ratio6.48 Quick Ratio6.42 Long Term Debt/Equity Debt Ratio0.1
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities19.59 M Cash From Investing Activities-750 K Cash From Operating Activities-2.41 M Gross Profit140 K
Net Profit-4.29 M Operating Profit-4.3 M Total Assets57.94 M Total Current Assets32.6 M
Total Current Liabilities5.03 M Total Debt Total Liabilities5.27 M Total Revenue600 K
Technical Data
High 52 week23.65 Low 52 week12.32 Last close16.86 Last change-1.58%
RSI49.77 Average true range0.71 Beta0.69 Volume15.97 K
Simple moving average 20 days0.84% Simple moving average 50 days-1.55% Simple moving average 200 days-6.85%
Performance Data
Performance Week1.26% Performance Month-0.24% Performance Quart-13.8% Performance Half-4.2%
Performance Year-6.59% Performance Year-to-date-4.53% Volatility daily3.55% Volatility weekly7.94%
Volatility monthly16.27% Volatility yearly56.35% Relative Volume249.32% Average Volume46.49 K
New High New Low

News

2020-05-27 17:20:15 | Hedge Funds Are Warming Up To Cellular Biomedicine Group, Inc. CBMG

2020-05-26 08:00:00 | Cellular Biomedicine Group CBMG Announces 2020 Annual Meeting of Stockholders

2020-05-07 15:31:08 | Cellular Biomedicine Group Inc CBMG Q1 2020 Earnings Call Transcript

2020-05-07 07:29:44 | Edited Transcript of CBMG earnings conference call or presentation 6-May-20 9:00pm GMT

2020-05-06 16:16:00 | Cellular Biomedicine Group Reports Q1 2020 Financial Results and Business Highlights

2020-05-01 16:15:00 | Cellular Biomedicine Group to Report First Quarter 2020 Results on May 6, 2020

2020-02-28 16:05:00 | Cellular Biomedicine Group Announces Q4 and Full Year 2019 Financial Results and Recent Operational Progress

2020-02-26 09:00:00 | Cellular Biomedicine Group to Report Fourth Quarter and Full Year 2019 Results on February 28, 2020

2019-12-30 08:30:00 | Cellular Biomedicine Group Announces Engagement of Independent Advisors by Special Committee

2019-12-10 16:00:01 | China’s Curing Cancer Faster and Cheaper Than Anywhere Else

2019-12-07 08:00:00 | Cellular Biomedicine Group Presents First Clinical Data of IIT Phase 1 Trial of C-CAR088, a Novel BCMA CAR-T, at the 61st Annual Meeting of the American Society of Hematology

2019-11-27 16:17:30 | This Hedge Fund Bought Cellular Biomedicine Group, Inc. CBMG At The Right Time

2019-11-15 04:50:00 | CBMG: Data from Multiple Myeloma Trial to be Presented at ASH…

2019-11-11 10:00:00 | Cellular Biomedicine Group Announces Receipt of a Preliminary Non-Binding _Going Private_ Proposal

2019-11-11 01:05:08 | Edited Transcript of CBMG earnings conference call or presentation 6-Nov-19 9:30pm GMT

2019-11-06 16:36:00 | Cellular Biomedicine Group Reports Third Quarter of 2019 Financial Results and Business Highlights

2019-10-30 08:00:00 | Cellular Biomedicine Group to Report Third Quarter 2019 Results on November 6, 2019

2019-10-04 10:28:00 | Is Cellular Biomedicine Group NASDAQ:CBMG A Risky Investment?

2019-10-02 08:37:00 | Cellular Biomedicine Group Announces New Facility to Expand Research and Development and to Support Clinical Development

2019-10-01 16:30:00 | Cellular Biomedicine Group to Present at the 2019 Cantor Global Healthcare Conference

2019-09-30 06:30:00 | CBMG: Initiating Coverage of Cellular Biomedicine Group; Multiple Cell-Based Therapies to Treat Cancer and Degenerative Diseases…

2019-09-27 22:49:00 | Cellular Biomedicine Group's ReJoin® Therapy Receives Stem Cell Drug Application Acceptance For Phase II Clinical Trials by China NMPA

2019-09-12 07:30:00 | Cellular Biomedicine Group Hosts Meeting with Investigators to Launch AlloJoin® Knee Osteoarthritis Phase II Clinical Trial

2019-09-09 09:28:00 | Cellular Biomedicine Group to Present at 5th Annual CAR-TCR Summit in Boston

2019-08-29 08:31:00 | Cellular Biomedicine Group to Present at Baird's 2019 Global Healthcare Conference

2019-08-20 13:34:35 | Should You Be Pleased About The CEO Pay At Cellular Biomedicine Group, Inc.'s NASDAQ:CBMG

2019-08-08 16:34:40 | Edited Transcript of CBMG earnings conference call or presentation 6-Aug-19 8:30pm GMT

2019-08-08 11:05:06 | Cellular Biomedicine Group Inc CBMG Q2 2019 Earnings Call Transcript

2019-08-06 16:10:00 | Cellular Biomedicine Group Reports Second Quarter and First Half of 2019 Financial Results and Business Highlights

2019-07-23 08:40:00 | Cellular Biomedicine Group to Report Second Quarter 2019 Results on August 6, 2019

2019-06-27 14:29:57 | If You Had Bought Cellular Biomedicine Group NASDAQ:CBMG Stock Three Years Ago, You Could Pocket A 25% Gain Today

2019-06-18 07:30:00 | ­Cellular Biomedicine Group Executives to Present at CAR-TCR Summit Asia

2019-06-17 07:00:00 | Cellular Biomedicine Group Announces First Patient Dosing in Phase I Clinical Trial of Anti-CD20 CAR-T for Lymphoma in China

2019-05-29 08:45:00 | Cellular Biomedicine Group to Present at International Society for Cell and Gene Therapy Annual Meeting

2019-05-20 08:00:00 | Cellular Biomedicine Group to Present at B. Riley FBR Annual Investor Conference

2019-05-17 12:04:41 | Do Directors Own Cellular Biomedicine Group, Inc. NASDAQ:CBMG Shares?

2019-05-02 17:59:21 | Edited Transcript of CBMG earnings conference call or presentation 1-May-19 12:30pm GMT

2019-04-30 19:40:39 | Cellular Biomedicine: 1Q Earnings Snapshot

2019-04-30 17:24:00 | Cellular Biomedicine Group Reports First Quarter 2019 Results and Highlights Operational Progress

2019-04-29 09:00:00 | Cellular Biomedicine Group Announces Results of 2019 Annual Meeting of Stockholders

2019-04-25 09:00:00 | Cellular Biomedicine Group to Report First Quarter 2019 Results and Host Conference Call on May 1, 2019

2019-04-23 08:30:00 | Cellular Biomedicine Group Upgraded to NASDAQ Global Select Market

2019-04-15 09:20:00 | Cellular Biomedicine Group to Participate in Asia Pharma R&D Leaders Summit 2019

2019-04-05 09:00:00 | Cellular Biomedicine Group to Present at Annual BioCentury Future Leaders in the Biotech Industry Conference

2019-04-03 16:39:00 | SHAREHOLDER ALERT: Monteverde & Associates PC Launches an Investigation of the Board of Directors and Officers

2019-04-03 14:57:10 | Our Take On Cellular Biomedicine Group, Inc.'s NASDAQ:CBMG CEO Salary

2019-03-28 09:00:00 | Cellular Biomedicine Group CBMG Announces Annual Meeting of Stockholders

2019-03-21 08:58:00 | Cellular Biomedicine Group Announces Pricing of Public Offering of Common Stock

2019-03-21 07:51:16 | The Daily Biotech Pulse: Biogen Plummets, FDA Greenlights Sleep Disorder Drug, Cellular Biomedicine Offering

2019-03-20 16:01:00 | Cellular Biomedicine Group Announces Proposed Follow-on Offering of Common Stock